This was further supported by a study showing that the combination of 2141-V11 and IL-15 enhances efficacy in preclinical bladder cancer models, as evidenced by a reduction in tumor burden and an increase in activated CD8+ T cells within the TME [91]. The gene discussed is CD8A; the disease is urinary bladder carcinoma.